BioSpace News Archive

Chameleon Biosciences Inc., a biotechnology company focused on an innovative approach to produce safer, more effective gene therapies, will present “Use of EVADER AAV8 for repeat dosing in mice and non-human primates” in poster form at ESGCT’s 29th annual conference in Edinburgh, Scotland, U.K.

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Mark Wiggins as Chief Business Officer and Jakub Simon as Chief Medical Officer.

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced an update from the ongoing global Phase 1 KN-8701 trial evaluating KIN-2787, an investigational pan-RAF inhibitor, in patients with BRAF-altered solid tumors and/or who have NRAS mutant melanoma.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the H.C. Wainwright 6th Annual NASH Virtual Investor Conference on Monday, October 17, 2022, at 12:00 p.m. E.T.

Elevar Therapeutics, Inc. announced a positive pre-New Drug Application meeting with the U.S. Food and Drug Administration for its investigational drug rivoceranib in combination with camrelizumab as a treatment option for hepatocellular carcinoma, the most common type of liver cancer and cause of more than 830,000 annual deaths worldwide.

Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced that it will present clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, at the upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting taking place November 8-12 in Boston.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2022 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on November 1, 2022.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today reported financial results for the second quarter ended June 30, 2022.

IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, has scheduled the release of its 2022 third quarter results for Tuesday, November 1, 2022 before the market opens.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has initiated DAZALS – a Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS).